Compare TANH & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | CMMB |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 8.4M |
| IPO Year | 2013 | 2023 |
| Metric | TANH | CMMB |
|---|---|---|
| Price | $12.51 | $1.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 124.8K | 29.6K |
| Earning Date | 12-18-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.17 | $30.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.92 |
| 52 Week High | $29.89 | $2.99 |
| Indicator | TANH | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 47.38 |
| Support Level | $12.62 | $0.99 |
| Resistance Level | $18.29 | $1.91 |
| Average True Range (ATR) | 4.12 | 0.13 |
| MACD | -0.18 | 0.06 |
| Stochastic Oscillator | 24.16 | 84.44 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.